Holen Sie sich die Stockscreener-App
0.1401
2.71%
-0.0039
Handel nachbörslich:
.14
-0.000100
-0.07%
Schlusskurs vom Vortag:
$0.144
Offen:
$0.1431
24-Stunden-Volumen:
1.75M
Relative Volume:
0.17
Marktkapitalisierung:
$18.99M
Einnahmen:
$1.73M
Nettoeinkommen (Verlust:
$-23.50M
KGV:
-0.6415
EPS:
-0.2184
Netto-Cashflow:
$-19.37M
1W Leistung:
-21.64%
1M Leistung:
-30.33%
6M Leistung:
-68.45%
1J Leistung:
-71.41%
1-Tages-Spanne:
$0.1351
$0.144
1-Wochen-Bereich:
$0.1351
$0.1717
52-Wochen-Spanne:
$0.1351
$0.94
VolitionRX Ltd Stock (VNRX) Company Profile
Firmenname
VolitionRX Ltd
Sektor
Branche
Telefon
646 650 1351
Adresse
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Compare VNRX vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
0.1401 | 18.99M | 1.73M | -23.50M | -19.37M | -0.2184 |
TMO
Thermo Fisher Scientific Inc
|
469.71 | 174.55B | 45.20B | 6.88B | 6.75B | 18.19 |
DHR
Danaher Corp
|
177.25 | 125.45B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
565.93 | 44.95B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
115.55 | 32.65B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
309.87 | 30.42B | 3.17B | 642.63M | 516.49M | 10.77 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-02-01 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-02-17 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-03-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-05-16 | Eingeleitet | Maxim Group | Buy |
| 2018-05-14 | Bestätigt | The Benchmark Company | Buy |
| 2016-09-07 | Bestätigt | Rodman & Renshaw | Buy |
| 2016-02-01 | Eingeleitet | Rodman & Renshaw | Buy |
Alle ansehen
VolitionRX Ltd Aktie (VNRX) Neueste Nachrichten
VolitionRX | 8-K: Current report - Moomoo
VolitionRx receives NYSE American compliance plan approval By Investing.com - Investing.com Australia
VolitionRx Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
VolitionRx (NYSE: VNRX) wins NYSE American time to fix listing - Stock Titan
VolitionRx shares stay on NYSE as exchange accepts compliance plan - Stock Titan
D Boral Capital downgrades VolitionRx (VNRX) - MSN
VolitionRx launches online shop for recombinant nucleosomes By Investing.com - Investing.com Australia
VNRX Downgraded by D. Boral Capital -- Rating Changed to Hold - GuruFocus
VolitionRx Ltd stock (US92852X1037): Does its blood-testing tech unlock real diagnostic upside? - AD HOC NEWS
D. Boral Capital downgrades VolitionRX stock rating on reverse split By Investing.com - Investing.com South Africa
D. Boral Capital Downgrades VolitionRX(VNRX.US) to Hold Rating - Moomoo
After building for 10 years, Volition puts nucleosomes up for sale online - Stock Titan
VolitionRx Limited Files Form 8-K With SEC Detailing Company Information and Compliance Data - Minichart
VolitionRx Ltd stock (US92852X1037): Is its blood-testing breakthrough strong enough to unlock inves - AD HOC NEWS
VolitionRx (VNRX) to execute 1-for-20 reverse stock split on April 28, 2026 - Stock Titan
VNRX Should I Buy - Intellectia AI
VNRX Stock Price, Quote & Chart | VOLITIONRX LTD (NYSEARCA:VNRX) - ChartMill
VolitionRx Ltd stock (US92852X1037): Why does its blood-testing innovation matter more now for U.S. - AD HOC NEWS
H.C. Wainwright cuts VolitionRX stock price target to $1 on share count - Investing.com Australia
VolitionRx Earnings Call: Breakthroughs Amid Funding Strain - TipRanks
VolitionRx Limited (VNRX) stock price, news, quote and history - Yahoo Finance UK
VNRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
VolitionRX (VNRX) FY2025 Earnings: Q4 EPS and Revenue Not Disclo - GuruFocus
VolitionRX Is Maintained at Buy by HC Wainwright & Co. - Moomoo
VolitionRx Limited (AMEX:VNRX) Q4 2025 Earnings Call Transcript - Insider Monkey
VolitionRX Q4 Earnings Call Highlights - Defense World
VolitionRX Ltd (VNRX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
VolitionRX Ltd (VNRX) Q4 2025 Earnings Call Highlights: Strong R - GuruFocus
VolitionRx: Robust Revenue Growth and Promising Capture-Seq Data Support Buy Rating Despite Dilution-Driven Target Cut - TipRanks
VolitionRX (VNRX) Sees Target Price Cut Despite Maintained Buy R - GuruFocus
VolitionRx Limited (VNRX) 8-K SEC Filing March 31, 2026: Company Details, Address, and Stock Information - Minichart
VolitionRx (NYSE: VNRX) wins approval for major share issue and reverse split - Stock Titan
Earnings call transcript: VolitionRx Q4 2025 reveals mixed financial results By Investing.com - Investing.com South Africa
Earnings call transcript: VolitionRx Q4 2025 reveals mixed financial results - Investing.com
Q4 2025 VolitionRX Ltd Earnings Call Transcript - GuruFocus
VolitionRx : Corporate Presentation April 2026 - marketscreener.com
VolitionRX's Nu.Q Cancer Reimbursement Decision in Q4 2026 Could Unlock Commercial Licensing Momentum Amid Dilution Risks - Bitget
VolitionRx secures €2M in Belgian government financing By Investing.com - Investing.com South Africa
Volitionrx Ltd earnings beat, revenue fell short of estimates By Investing.com - Investing.com India
Volitionrx Ltd earnings beat, revenue fell short of estimates - Investing.com UK
VolitionRX Q4 2025 Earnings Call Transcript - MarketBeat
VolitionRX: Q4 Earnings Snapshot - theheraldreview.com
VolitionRX (VNRX) Rating Maintained as Buy by D. Boral Capital | - GuruFocus
VolitionRx (NYSE: VNRX) details going concern risk, funding needs and Nu.Q® rollout - Stock Titan
Volition says its tests are nearing hospital use in lung cancer and sepsis - Stock Titan
VolitionRX Price Target Maintained With a $3.00/Share by D. Boral Capital - Moomoo
VolitionRX Ltd (VNRX) Q4 2025: Everything You Need to Know Ahead of Earnings - GuruFocus
Finanzdaten der VolitionRX Ltd-Aktie (VNRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.42%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):